0001127602-13-003953.txt : 20130204 0001127602-13-003953.hdr.sgml : 20130204 20130204170027 ACCESSION NUMBER: 0001127602-13-003953 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130131 FILED AS OF DATE: 20130204 DATE AS OF CHANGE: 20130204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZAMBROWICZ BRIAN P CENTRAL INDEX KEY: 0001226231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 13570799 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGH FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2013-01-31 0001062822 LEXICON PHARMACEUTICALS, INC./DE LXRX 0001226231 ZAMBROWICZ BRIAN P 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381 1 EVP, Chief Scientific Officer Common Stock 2013-01-31 4 M 0 42100 A 216580 D Common Stock 2013-01-31 4 F 0 13499 2.11 D 203081 D Restricted Stock Units (Phantom Stock) 2013-01-31 4 M 0 42100 D Common Stock 42100 0 D Each restricted stock unit represents a contingent right to receive one share of common stock. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent. /s/ Brian P. Zambrowicz, Ph.D. 2013-02-01